drugset / Trial / NCT03658330

Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

NCT03658330

Phase 2 Completed 5 enrolled VA Connecticut Healthcare System
NaSingle-groupOpen-labelTreatment

Summary

To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.

Timeline

Start
2016-05
Primary completion
2016-10
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intravenous
Subject Naltrexone Small molecule 380 mg Intramuscular